<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837638</url>
  </required_header>
  <id_info>
    <org_study_id>FH-CAC (MP-20-2021-5767)</org_study_id>
    <nct_id>NCT04837638</nct_id>
  </id_info>
  <brief_title>Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia</brief_title>
  <acronym>FH-CAC</acronym>
  <official_title>Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recheche du Centre Hospitalier Université Laval</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching objective is to evaluate the relationship between diet and coronary artery&#xD;
      calcification in patients with heterozygous familial hypercholesterolemia (HeFH). We will&#xD;
      recruit adults with HeFH. They will have to complete questionnaires on diet, medication and&#xD;
      lifestyle. Coronary artery calcification will be measured in each patient using a CT scan.&#xD;
      Physiological and biochemical data will be collected.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed research will deploy as cross-sectional study including treated adults with&#xD;
      genetically-defined HeFH. Once recruited, participants will be asked to complete web-based&#xD;
      questionnaires on diet, medication and lifestyle. They will thereafter complete a clinical&#xD;
      assessment at the Clinical Investigation Unit of the NUTRISS-INAF Research Centre. Study&#xD;
      staff will measure participants' height, weight, and waist circumference. Participants' blood&#xD;
      pressure will be measured using an automatic blood pressure monitor (BP Thru, Omron) after&#xD;
      sitting quietly for 10 minutes. Three sequential readings will be taken with three minutes&#xD;
      between readings. Fasting blood samples (10 mL) will be collected from an antecubital vein.&#xD;
      Body composition will be assessed with dual-energy X-ray absorptiometry (DEXA). Finally,&#xD;
      participants will be asked to provide the full list of medication they are using, including&#xD;
      type, dose and duration of use. Later on the same day, participants will undergo the&#xD;
      non-contrast CT scan at the Quebec Heart and Lung Institute. Multidetector CT scans without&#xD;
      contrast will be performed using a 256 slices helical scanner (Brilliance iCT, Philips).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship between diet quality and coronary artery calcification (CAC)</measure>
    <time_frame>Diet questionnaire completion and CAC measurement will be completed with a 3 weeks period.</time_frame>
    <description>Diet quality indices reflecting different dimensions of diet will be used as the main exposure, including the Alternative Mediterranean Diet Index (AMED, 9-45 points), the Alternative Healthy Eating Index (AHEI, 0-100 points), the Dietary Approach to Stop Hypertension index (DASHi, 8-40 points), the healthy plant-based diet index (hPDI, 18-90 points) and the unhealthy plant-based diet index (uPDI, 18-90 points). Higher scores reflect higher diet quality, except for the uPDI which reflect lower diet quality. CAC will be measured using non-constrat CT scan. CAC scores will be quantified with the Agatston scoring method. Higher CAC scores reflect higher CAC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between diet quality and CVD risk factors.</measure>
    <time_frame>Diet questionnaire completion and CVD risk factor measurement will be completed with a 3 weeks period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between diet quality and psychological aspects of eating</measure>
    <time_frame>Diet questionnaire completion and psychological aspects of eating measurement will be completed with a 3 weeks period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between diet quality and lifestyle habits (physical activity, sleep, substance use, alcohol consumption, medication adherence)</measure>
    <time_frame>Diet questionnaire completion and lifestyle habit measurement will be completed with a 3 weeks period.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Hypercholesterolemia, Familial</condition>
  <condition>Calcification; Heart</condition>
  <condition>Diet Habit</condition>
  <arm_group>
    <arm_group_label>Adults with HeFH</arm_group_label>
    <description>Adult men and women aged 18 to 65 years with genetically-defined HeFH.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>No intervention. Cross-section assessment of the relationship between diet, medication, lifestyle and coronary artery calcification.</description>
    <arm_group_label>Adults with HeFH</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult men and women with genetically-defined HeFH&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Genetically-defined heterozygous familial hypercholesterolemia&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Homozygous FH&#xD;
&#xD;
          -  Personal history of cardiovascular disease&#xD;
&#xD;
          -  Personal history of cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe Drouin-Chartier</last_name>
    <role>Study Director</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Philippe Drouin-Chartier</last_name>
    <phone>418-656-2131</phone>
    <phone_ext>404072</phone_ext>
    <email>jean-philipe.drouin-chartier@pha.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie Guay</last_name>
    <phone>418-656-2131</phone>
    <phone_ext>404005</phone_ext>
    <email>valerie.guay@fsaa.ulaval.ca</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Jean-Philippe Drouin-Chartier</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

